Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

Download All
In this online program, experts discuss how to best use BTK inhibitors to enhance patient care across multiple B-cell malignancies. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium in Orlando, and read expert commentaries on the new data to learn more about how and when to use BTK-targeted regimens for your patients with cancer.
Ian W. Flinn, MD, PhD
Program Director
Jan A. Burger, MD, PhD
Alexey Danilov, MD
John Pagel Headshot
John Pagel, MD, PhD

Downloadable Slidesets

Download these slides from our ASH 2019 live satellite symposium on safety and optimal use of BTK inhibitors to review the most current clinical data on treating patients with hematologic malignancies.

Alexey Danilov, MD Released: December 6, 2019

Download these slides from our ASH 2019 live satellite symposium on frontline of BTK inhibitors to review the most current clinical data on treating patients with MCL

Ian W. Flinn, MD, PhD
Program Director Released: December 6, 2019

Download these slides from our ASH 2019 live satellite symposium on frontline use of BTK inhibitors to review the most current clinical data on treating patients with CLL

John Pagel Headshot John Pagel, MD, PhD Released: December 6, 2019

Download these slides from our ASH 2019 live satellite symposium on safety and optimal use of BTK inhibitors to review the most current clinical data on treating patients with diverse hematologic malignancies.

John Pagel Headshot John Pagel, MD, PhD Released: December 6, 2019

Download these slides from our ASH 2019 live satellite symposium on overcoming resistance to BTK inhibitors to review the most current clinical data on treating patients with CLL.

Jan A. Burger, MD, PhD Released: December 6, 2019
Provided by Clinical Care Options, LLC
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue